Immunotherapies and renal injury

Current Opinion in Toxicology - Tập 31 - Trang 100362 - 2022
Aisha Shaikh1
1Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Tài liệu tham khảo

Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486

Krummel, 1995, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J Exp Med, 182, 459, 10.1084/jem.182.2.459

Fife, 2008, Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways, Immunol Rev, 224, 166, 10.1111/j.1600-065X.2008.00662.x

Greenwald, 2005, The B7 family revisited, Annu Rev Immunol, 23, 515, 10.1146/annurev.immunol.23.021704.115611

Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol Cell Biol, 25, 9543, 10.1128/MCB.25.21.9543-9553.2005

Iwai, 2017, Cancer immunotherapies targeting the PD-1 signaling pathway, J Biomed Sci, 24, 26, 10.1186/s12929-017-0329-9

Qin, 2019, Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4, Mol Cancer, 18, 155, 10.1186/s12943-019-1091-2

Boutros, 2016, Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat Rev Clin Oncol, 13, 473, 10.1038/nrclinonc.2016.58

Centanni, 2019, Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors, Clin Pharmacokinet, 58, 835, 10.1007/s40262-019-00748-2

Cortazar, 2020, Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study, J Am Soc Nephrol, 31, 435, 10.1681/ASN.2019070676

Gupta, 2021, Acute kidney injury in patients treated with immune checkpoint inhibitors, J Immunother Cancer, 9, 10

Meraz-Muñoz, 2020, Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes, J Immunother Cancer, 8, 6

García-Carro, 2021, Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors, Nephrol Dial Transplant

Qualls, 2019, Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis, J Immunother Cancer, 7, 12

Isik, 2021, Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events, Kidney Int Rep, 6, 1022, 10.1016/j.ekir.2021.01.013

Faje, 2018, High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma, Cancer, 124, 3706, 10.1002/cncr.31629

Thompson, 2020, NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020, J Natl Compr Cancer Netw, 18, 230, 10.6004/jnccn.2020.0012

Belliere, 2021, Renal complications related to checkpoint inhibitors: diagnostic and therapeutic strategies, Diagnostics, 11, 10.3390/diagnostics11071187

Lee, 2021, Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study, J Immunother Cancer, 9, 4

Lin, 2021, Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis, OncoImmunology, 10, 10.1080/2162402X.2021.1877415

Kitchlu, 2021, A systematic review of immune checkpoint inhibitor-associated glomerular disease, Kidney Int Rep, 6, 66, 10.1016/j.ekir.2020.10.002

Mamlouk, 2019, Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience, J Immunother Cancer, 7

Fadel, 2009, Anti-CTLA4 antibody-induced lupus nephritis, N Engl J Med, 361, 211, 10.1056/NEJMc0904283

Glutsch, 2019, Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy, J Immunother Cancer, 7, 181, 10.1186/s40425-019-0655-4

Cortazar, 2016, Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors, Kidney Int, 90, 638, 10.1016/j.kint.2016.04.008

Cruz-Whitley, 2020, Membranoproliferative glomerulonephritis associated with nivolumab therapy, Case Rep Nephrol, 2020

Lin, 2020, Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab, J Immunother Cancer, 8, 10

Wanchoo, 2017, Adverse renal effects of immune checkpoint inhibitors: a narrative review," (in eng), Am J Nephrol, 45, 160, 10.1159/000455014

Uppal, 2022, Electrolyte and acid-base disorders associated with cancer immunotherapy, Clin J Am Soc Nephrol, 10.2215/CJN.14671121

Seethapathy, 2021, Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors, Nephrol Dial Transplant, 36, 2241, 10.1093/ndt/gfaa272

Doodnauth, 2021, A rare presentation of checkpoint inhibitor induced distal RTA, Case Rep Oncol Med, 2021

Farid, 2020, Immune checkpoint inhibitor-induced fanconi syndrome, Cureus, 12

Herrmann, 2020, Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-A report of 3 cases, Kidney Med, 2, 657, 10.1016/j.xkme.2020.05.015

DeFranco, 1995, Absence of vacuolar H(+)-ATPase pump in the collecting duct of a patient with hypokalemic distal renal tubular acidosis and Sjögren's syndrome, J Am Soc Nephrol, 6, 295, 10.1681/ASN.V62295

Abdel-Rahman, 2016, Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis, Future Oncol, 12, 413, 10.2217/fon.15.222

Berthod, 2012, Pulmonary sarcoid-like granulomatosis induced by ipilimumab, J Clin Oncol, 30, e156, 10.1200/JCO.2011.39.3298

Tetzlaff, 2018, Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients, J Immunother Cancer, 6, 14, 10.1186/s40425-018-0323-0

Deligiorgi, 2019, Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions, Int Immunopharm, 77, 10.1016/j.intimp.2019.105942

Champiat, 2017, Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1, Clin Cancer Res, 23, 1920, 10.1158/1078-0432.CCR-16-1741

Shah, 2020, Pembrolizumab-axitinib-induced tumor lysis syndrome in a patient with metastatic renal cancer, Clin Case Rep, 8, 704, 10.1002/ccr3.2737

Lipson, 2016, Tumor regression and allograft rejection after administration of anti-PD-1," (in eng), N Engl J Med, 374, 896, 10.1056/NEJMc1509268

Abdel-Wahab, 2019, Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature, J Immunother Cancer, 7, 106, 10.1186/s40425-019-0585-1

Manohar, 2020, Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients, Kidney Int Rep, 5, 149, 10.1016/j.ekir.2019.11.015

Portuguese, 2022, Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review, J Natl Compr Cancer Netw, 20, 406, 10.6004/jnccn.2022.7009

Murakami, 2021, A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant, Kidney Int, 100, 196, 10.1016/j.kint.2020.12.015

Adam, 2021, Gene expression profiling in kidney transplants with immune checkpoint inhibitor-associated adverse events, Clin J Am Soc Nephrol, 16, 1376, 10.2215/CJN.00920121

Barnett, 2017, Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab, N Engl J Med, 376, 191, 10.1056/NEJMc1614298

Kitchlu, 2021, Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review, Clin Kidney J, 14, 2012, 10.1093/ckj/sfab090

Hong, 2020, Engineering CAR-T cells for next-generation cancer therapy, Cancer Cell, 38, 473, 10.1016/j.ccell.2020.07.005

Chang, 2017, CARs: synthetic immunoreceptors for cancer therapy and beyond," (in eng), Trends Mol Med, 23, 430, 10.1016/j.molmed.2017.03.002

Gupta, 2020, Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma, Am J Kidney Dis, 76, 63, 10.1053/j.ajkd.2019.10.011

Gutgarts, 2020, Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery, Biol Blood Marrow Transplant, 6, 1071, 10.1016/j.bbmt.2020.02.012

Lee, 2021, Acute kidney injury after the CAR-T therapy tisagenlecleucel, Am J Kidney Dis, 77, 990, 10.1053/j.ajkd.2020.08.017

Kanduri, 2021, Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies, Kidney Int Rep, 6, 1416, 10.1016/j.ekir.2021.02.013

2016, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia; chimeric antigen receptor-modified T cells for acute lymphoid leukemia; chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 374, 998, 10.1056/NEJMx160005

Acharya, 2021, Collapsing focal segmental glomerulosclerosis and acute kidney injury associated with chimeric antigen receptor T-cell (CAR-T) therapy: a case report, Kidney Med, 3, 1086, 10.1016/j.xkme.2021.06.011

Durlacher-Betzer, 2018, Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease, Kidney Int, 94, 315, 10.1016/j.kint.2018.02.026

Krishnamoorthy, 2021, CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder, Am J Transplant, 21, 809, 10.1111/ajt.16367

Mamlouk, 2021, Safety of CAR T-cell therapy in kidney transplant recipients, Blood, 137, 2558, 10.1182/blood.2020008759

Thông tin
Thông tin xuất bản

Current Opinion in Toxicology

Tập 31

100362

Thông tin tác giả